NCT05903183View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

July 5, 2025

Study Completion Date

September 30, 2025

Conditions
Healthy
Interventions
BIOLOGICAL

IVX-A12

IVX-A12 without adjuvant

BIOLOGICAL

IVX-A12

IVX-A12 with adjuvant

BIOLOGICAL

Placebo

Diluent

Trial Locations (10)

14609

Rochester Clinical Research, Inc, Rochester

30281

Clinical Research Atlanta, Stockbridge

33024

Cenexel RCA, Hollywood

40509

AMR Lexington, Lexington

66219

Johnson City Clin-Trials (JCCT), Lenexa

68134

Velocity Clinical Research, Omaha

78520

PanAmerican Clinical Research, Brownsville

83587

ASR, LLC, Nampa

83642

Velocity Clinical Research-Boise, Meridian

85281

AMR Phoenix, Tempe

Sponsors

Lead Sponsor

Icosavax, Inc.
All Listed Sponsors
lead

Icosavax, Inc.

INDUSTRY

NCT05903183 - A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age | Biotech Hunter | Biotech Hunter